Lexeo Therapeutics, Inc.

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. On October 12, 2023, Rocket filed a lawsuit in the U.S. District Court for the Southern District of New York against Lexeo and two former employees claiming, among other things, misappropriation of confidential information and trade secrets. The complaint alleges that while employees of Rocket, the individual defendants downloaded confidential Rocket company documents and other proprietary materials and that Lexeo used this information to advance its programs after the individuals became employed by Lexeo. The complaint seeks unspecified damages and injunctive relief. In August 2024, we asserted counterclaims against Rocket and Spacecraft Seven LLC, a wholly owned subsidiary of Rocket, for misappropriation of trade secrets, correction of inventorship of certain PKP2-ACM patents, breach of contract, and tortious interference with contract in connection with their diligence of a PKP2-ACM program at UCSD that was later licensed by Lexeo. Our counterclaims seek equitable relief, damages, attorneys' fees and costs from Rocket and Spacecraft Seven LLC. The case is currently in the discovery phase. While it is not possible to predict the outcome with certainty and an estimate of the possible loss cannot be made, we currently do not expect the final outcome will have a material adverse effect on our timelines for development of our product candidates. Regardless of the final outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, harm to our reputation and other factors.